A Win For Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ) rocketted today at $3.39, representing a gain of 40.1%. On Wed 20 Nov 19, HEPA:NASDAQ touched a New 2-Week Low of $2.42. The stock featured on our News Catalysts scanner on Thu 21 Nov 19 at 08:55 AM. From Thu 31 Oct 19, the stock recorded 28.57% Up Days and 26.67% Green Days
The stock spiked on Thu 17 Oct 19 at $5.59 with a volume of 37M+.
The share price of the company has been moving sideways in recent weeks.
About Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ)
ContraVir Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. The company focuses on developing two novel oral compounds to treat HBV infection. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. TXL is a nucleotide pro-drug of tenofovir that inhibits hepatitis B viral replication and targets the liver, the reservoir for the hepatitis B virus.
Top 10 Gainers:
- Wah Fu Education Group Limited (WAFU:NASDAQ), 137.07%
- Stage Stores, Inc. (SSI:NYSE), 52.02%
- 22nd Century Group, Inc. (XXII:NYSEMKT), 42.86%
- Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ), 40.08%
- McDermott International, Inc. (MDR:NYSE), 33.84%
- HEXO Corp. (HEXO:NYSEMKT), 33.68%
- HEXO Corp. (HEXO:NYSE), 33.68%
- Seneca Biopharma, Inc. (SNCA:NASDAQ), 29.87%
- NF Energy Saving Corporation (BIMI:NASDAQ), 25%
- CTI Industries Corporation (CTIB:NASDAQ), 24.61%